Finally, we identified that PLK4 sensitives HCC to CFI‐400945, a small‐molecule inhibitor of PLK4 undergoing phase II clinical trial testing in breast cancer and prostate cancer,17, 18 which provided a potential therapy target for HCC. This evidence concerns the gene PLK4 and Familial prostate cancer.